US clears Merck’s Keytruda for head and neck cancer
Merck’s immunotherapy Keytruda has picked up yet another regulatory approval – this time in the US as a treatment for head and neck cancer.
Read More
Tag: KEYNOTE-012
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
